Interceptor Plus 11.5 mg Tablet is a Health Canada–registered veterinary drug (DIN 02468360) held by Elanco Canada Limited, containing Milbemycin Oxime. Health Canada lists its status as Marketed (status date 13 Jun 2018). Nexara Health has matched 10 registrations of Milbemycin Oxime across 1 other regulated market.
Health Canada registration
| DIN | 02468360 |
|---|---|
| Brand name | Interceptor Plus |
| Active ingredient | Milbemycin Oxime |
| Strength | 11.5 mg |
| Dosage form | Tablet |
| Route | Oral |
| Company | Elanco Canada Limited |
| Status | Marketed — 13 Jun 2018 |
| Class | Veterinary |
| ATC | |
| AHFS | |
| Regulator record | Health Canada DPD entry · Product monograph |
Milbemycin Oxime registered in other markets
10 registrations of the same molecule in 1 national registry outside Canada (first 8 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| United States | milbemycin oxime | Elanco US Inc. | Tablet | FDA NDC | ||
| United States | milbemycin oxime | Elanco US Inc. | Tablet | FDA NDC | ||
| United States | milbemycin oxime | Elanco US Inc. | Tablet | FDA NDC | ||
| United States | milbemycin oxime | Elanco US Inc. | Tablet | FDA NDC | ||
| United States | Milbemycin Oxime | Zhejiang Hisun Pharmaceutical Co., Ltd. | Powder | FDA NDC | ||
| United States | Milbemycin Oxime | Hubei Honch Pharmaceutical Co., Ltd. | Powder | FDA NDC | ||
| United States | Milbemycin Oxime | Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd. | Powder | FDA NDC | ||
| United States | Milbemycin Oxime | Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd. | Powder | FDA NDC |
See every manufacturer of Milbemycin Oxime worldwide →
Marketed Canadian products with the same active ingredient
| DIN | Product | Company | Strength | Form |
|---|---|---|---|---|
| 02468352 | Interceptor Plus | Elanco Canada Limited | 57 mg | Tablet |
| 02468344 | Interceptor Plus | Elanco Canada Limited | 22.8 mg | Tablet |
| 02468379 | Interceptor Plus | Elanco Canada Limited | 228 mg | Tablet |
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. Because this DIN is marketed in Canada, supply normally comes through the Canadian channel; where the Canadian presentation is short or discontinued, the registrations above show which regulated markets hold an equivalent that can be imported under the Special Access Programme or for clinical comparator use. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Interceptor Plus (DIN 02468360) marketed in Canada?
Yes. Health Canada lists DIN 02468360 as Marketed as of 13 Jun 2018.
Who holds the Canadian licence for this product?
Elanco Canada Limited is the company of record in the Health Canada Drug Product Database.
Is Milbemycin Oxime registered outside Canada?
Yes — Nexara Health has matched 10 registrations in 1 other market (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02468360, status date 2018-06-13; national medicine registries: FDA NDC. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02468360, status date 2018-06-13; national medicine registries: FDA NDC.
Health Canada Drug Product Database (DPD), DIN 02468360, status date 2018-06-13; national medicine registries: FDA NDC. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.